$ETST Earth Science Tech, Inc. Announces Partnership with Bionatus to Help Manufacture, Distribute, & Continue Further R&D on Cannabis (CBD) Products
GlobeNewswire•August 22, 2017
Hollywood, FL, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical, and medical device research and development, announces a strategic partnership with the new Canadian division of Brazil’s Bionatus Pharmaceutical Laboratory.
The two companies will initially cooperate to improve two of Bionatus’ existing products that have been successful in the Brazilian market, and then launch them in the USA. Both products are in liquid form.
Propovit is a spray with ingredients derived from honey. It is used to refresh the mouth and relieve sore throat symptoms.
The second product, BioToss is a syrup that helps in the treatment of respiratory disorders by facilitating the expectoration of phlegm and other secretions. This product contains Mikania glomerata extracts that have both bronchodilator and expectorant benefits.
Both Propovit and BioToss are compatible with ETST’s High Grade CBD-rich Hemp Oil. Under the agreement, ETST will be the exclusive provider of this critical component of the new, improved formulas. In addition, ETST will be the exclusive distributor of these products in the USA for a five-year period.
Dr. Michel Aube, ETST’s CEO & CSO updates with, “we have selected the research center that will conduct the in vitro assays to demonstrate the efficiency of the nutraceuticals in the ETST product pipeline which are based on the company’s International Provisory Patent Application. As recently announced, we will soon deliver the formulas to the Centre De Développement Bioalimentaire Du Québec Inc., (CDBQ) for mass formula conversion. Thereafter, the new partner that will test the products’ biological activity will be announced. We are also finalizing the logistics of the launch of the much-awaited MSN-2 medical device with its partner, Michel Gauthier, MD. That are on schedule for the anticipated Q1 2018 product launch. Doctors and Public Health Officials from many countries are waiting for the product to be released. The recent agreements with the communications agency Absolu, alongside the participation of Dr. Gauthier, will accelerate these final preparations.”
“This new partnership offers ETST a new distribution channel, specialized formulas to market, and remedies to those in need. I personally suffered from asthma as a child and took many pharmaceuticals with side effects to help with the symptoms. I know our current CBD oil has helped many with asthma based on many customer positive feedback but, now thanks to Dr. Michel Aube and the new partnership with Bionatus he has formed, we are now able to formulate a product specifically for asthmatics and offer an alternative to individuals struggling with asthma as I did as a child. I look forward on sharing updates on all of Dr. Aube’s projects as they progress and on many exciting achievements on our new KannaBidioid subsidiary, and product distribution very soon.” ended Nickolas S. Tabraue, ETST, president, director, and COO.
AI
